Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors
Leading industry expert with more than 25 years of experience in translation research in immunology
Basel, Switzerland, 23 May 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D’Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
